IL-10 Checkpoint Combination Therapy for Low-Mutation Tumors

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing immune checkpoint pathway modulators show diminished efficacy in tumors with low tumor mutation burden and low expression of PD-L1 or IFNγ, limiting their effectiveness in treating neoplastic diseases.

Innovation Solution

Combining interleukin-10 (IL-10) agents with modulators of immune checkpoint pathways, such as PD1 inhibitors, to enhance immune response in neoplastic diseases, particularly in tumors with low or intermediate tumor mutation burden and low PD-L1 expression.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If immune checkpoint pathway modulators are used alone, then immune response is enhanced in tumors with high mutation burden and high PD-L1 expression, but efficacy is diminished in tumors with low mutation burden and low PD-L1 expression

Engineering Contradiction:

Improveefficacy of immune checkpoint pathway modulatorsVSAvoideffectiveness across different tumor types and mutation burdens

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent combines IL-10 agents with immune checkpoint pathway modulators into a single combination therapy regimen. This merging of two therapeutic approaches creates a synergistic effect that overcomes the limitations of monotherapy, particularly in tumors with low mutation burden and low PD-L1 expression where checkpoint inhibitors alone show diminished efficacy.

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The treatment approach uses a composite therapeutic strategy combining two distinct mechanisms of action: IL-10-mediated immune modulation and immune checkpoint pathway inhibition. This composite approach integrates multiple therapeutic modalities to create a more robust and versatile treatment that adapts to diverse tumor characteristics.

Inventive Principle:

Principle #40Composite materials

2Reliability

If combination therapy with IL-10 and immune checkpoint inhibitors is used, then tumor burden is reduced and clinical outcomes are enhanced, but treatment complexity increases

Engineering Contradiction:

Improveclinical outcomes in neoplastic diseasesVSAvoidcombination therapy regimen

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent employs preliminary action by administering IL-10 agents before or concurrently with immune checkpoint pathway modulators to prime the immune system. This preparatory step enhances the subsequent effectiveness of checkpoint inhibition, creating a more potent therapeutic effect while managing treatment complexity through structured sequencing.

Inventive Principle:

Principle #10Preliminary action

Data Source

PatentUS12589134B2Compositions and methods of use of interleukin-10 in combination with immune check-point pathway inhibitors

Publication Date: 2026.03.31 ELI LILLY & CO

AI summary

The present disclosure provides a method for the treatment of neoplastic disease in a mammalian subject the method comprising the administration of an IL-10 agent in combination with the administration of at least one modulator of at least one immune checkpoint pathway. The present disclosure further provides a method for the treatment of neoplastic disease wherein the neoplasm has a low or intermediate tumor mutation burden, low or intermediate level of expression of the immune checkpoint molecule, or metastatic neoplastic disease.